Dopamine is a neurotransmitter involved in the reward pathways in the brain, and its decreased activity has been associated with diseases such as Parkinson's disease and attention-deficit/hyperactivity disorder (ADHD). Which of the following drugs is NOT a likely candidate to treat these diseases?

A. Methylphenidate, a dopamine reuptake inhibitor

B. Amphetamine, a dopamine-releasing agent that triggers the release of dopamine into the synaptic cleft

C. Carbidopa, which enhances the availability of the dopamine synthesis precursors in the brain

D. Forskolin, a sensitizer of dopamine receptors

E. Chlorpromazine, a dopamine antagonist that binds to and inhibits dopamine receptors

Question

Snowball

Biology

22 August, 10:22

Dopamine is a neurotransmitter involved in the reward pathways in the brain, and its decreased activity has been associated with diseases such as Parkinson's disease and attention-deficit/hyperactivity disorder (ADHD). Which of the following drugs is NOT a likely candidate to treat these diseases?

A. Methylphenidate, a dopamine reuptake inhibitor

B. Amphetamine, a dopamine-releasing agent that triggers the release of dopamine into the synaptic cleft

C. Carbidopa, which enhances the availability of the dopamine synthesis precursors in the brain

D. Forskolin, a sensitizer of dopamine receptors

E. Chlorpromazine, a dopamine antagonist that binds to and inhibits dopamine receptors

+2

Answers (2)

Know the Answer?

Destiny Mendoza · Answer 1

The answer should be amphetamine a dopamine release agent that triggers the

Cooper Valencia · Answer 2

The answer is E; Chlorpromazine, a dopamine antagonist that binds to and inhibits dopamine receptors

Explanation:

Chlorpromazine which is a dopamine antagonist is not a candidate to treat Parkinson's disease and attention-deficit/hyperactivity disorder (ADHD) because as a dopamine antagonist it works by binding to dopamine receptors but does not activate it, thus blocking the actions of dopamine or exogenous agonists.